Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


F-star Alpha Ltd.

Bispecific antibodies with modified “constant” regions

This article was originally published in Start Up

Executive Summary

F-star Alpha Ltd., a UK-based start-up recently spun out of F-star Biotechnology Ltd., believes its method of making bispecific antibodies can produce powerful therapeutics that are also easy to manufacture. While the parent company says the spin-out is essentially a commercial vehicle meant to leverage the value of the parent company's technology platform, F-star Alpha is dedicated to developing bispecific antibodies and antibody fragments as cancer treatments.


Related Content

Infectious Disease, Options Prevalent In 2014 Start-Up Dealmaking
Strategic Spin-Outs: Biotechs Structure Their Progeny For Success


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts